Characterization of the potent 5-HT1A/B receptor antagonist and serotonin reuptake inhibitor SB-649915: Preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy

CNS Drug Reviews

Volumn 13, Issue 2, 2007, Pages 206-223

  Watson, Jeannette M ^a   Dawson, Lee A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT reuptake; 5 HT1A receptor; 5 HT1B receptor; Antagonist; Autoreceptor; Dorsal raphe neuron (DRN); Electrophysiology; Microdialysis; SB 649915

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 (2 DIMETHYLAMINOETHYL) 4 CHLORO 5 PROPOXYINDOLE; 6 [[1 [2 [(2 METHYLQUINOLIN 5 YL)OXY]ETHYL]PIPERIDIN 4 YL]METHYL] 2H 1,4 BENZOXAZIN 3 (4H)ONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; PINDOLOL; RADIOLIGAND; SB 649915; SEROTONIN 1A ANTAGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANXIETY DISORDER; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; BRAIN SYNAPTOSOME; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; EX VIVO STUDY; FOREBRAIN; IN VITRO STUDY; IN VIVO STUDY; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; REVIEW; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZOXAZINES; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; PIPERIDINES; QUINOLINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN UPTAKE INHIBITORS;

EID: 34447298851     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2007.00012.x     Document Type: Review

References (87)

1. Adham N, Romanienko P, Hartig P, Weinshank RL, Brancheck TA (1992) The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-HT1Dβ receptor. Mol Pharmacol 41 : 1 7.
2. Artigas F, Celada P, Laruelle M, Adell A (2001) How does pindolol improve antidepressant action? TIPS 22 : 224 228.
3. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51 : 48 51.
4. Artigas F, Romero L, De Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. TINS 19 : 378 383.
5. Atkinson PJ, Bromidge SM, Duxon MS, Gaster LM, Hadley MS, Hammond B, Johnson CN, Middlemiss DN, North SE, Price GW, et al. (2005) 3,4-Dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg Med Chem Lett 15 : 737 741.
6. Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15 : 243 245.
7. Berton O, Durand M, Aguerre S, Mormede P, Chaouloff F (1999) Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 92 : 327 341.
8. Beyer CE, Boikess SR, Luo B, Dawson LA (2002) Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: An in vivo microdialysis study. J Psychopharmacol 16 : 297 304.
9. Bianchi M, Hagan JJ, Heidbreder CA (2005) Neuronal plasticity, stress and depression: Involvement of the cytoskeletal microtubular system? Curr Drug Targets CNS Neurol Disord 4 : 597 611.
10. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15 : 217 222.
11. Blier P, Bouchard C (1994) Modulation of 5-HT release in the guinea-pig brain following long term administration of antidepressant drugs. Br J Pharmacol 113 : 485 495.
12. Blier P, DeMontigny C (1983) Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3 : 1270 1278.
13. Blier P, Chaput Y, DeMontigny C (1988) Long-term 5-HT uptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: An electrophysiologic study in the rat brain. Arch Pharmacol 337 : 246 254.
14. Blier P, De Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 7 : 24 35.
15. Boulenguez P, Rawlins JN, Chauveau J, Joseph MH, Mitchell SN, Gray JA (1996) Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: Involvement of the hippocampo-accumbens pathway. Neuropharmacology 35 (11 1521 1529.
16. Casanovas JM, Hervas I, Artigas F (1999) Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex. Neuroreport 10 : 1441 1445.
17. Celine F, Ouissame MF, Nasser H (2006) Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 6 : 235 245.
18. Chaput Y, De Montigny C, Blier P (1986) Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn Schmiedeberg's Arch Pharmacol 333 : 342 348.
19. Clifford EM, Gartside SE, Umbers V, Cowen PJ, Hajos M, Sharp T (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. Br J Pharmacol 124 : 206 212.
20. Consolo S, Arnaboldi S, Ramponi S, Nannini L, Ladinsky H, Baldi G (1996) Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5-HT1B receptors. J Pharmacol Exp Ther 277 : 823 830.
21. Corradetti R, Laaris N, Hanoun N, LePoul E, Hamon M, Lanfumey L (1998) Antagonist properties of (-)-pindolol and WAY100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain. Br J Pharmacol 123 : 449 462.
22. Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988a) Zaclopride: Anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40 : 302 305.
23. Costall B, Domeney AM, Gerrard PA, Naylor RJ (1988b). A primate model for the assessment of anxiolytic drug action. Br J Pharmacol 95 (suppl 670P.
24. Davidson C, Stamford JA (1995) Evidence that 5-HT release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114 : 1107 1109.
25. Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, Arban R, Poffe A, Melotto S, Hagan JJ, et al. (2006) Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)- 2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic activity. Neuropharmacol 50 : 975 983.
26. Dawson LA, Nguyen HQ (1998) Effects of the 5-HT1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur J Pharmacol 345 : 41 46.
27. Dawson LA, Nguyen HQ, Smith DI, Schechter LE (2000) Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: A microdialysis study. Br J Pharmacol 130 : 797 804.
28. Dawson LA, Nguyen HQ, Smith DI, Schechter LE (2002) Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 16 : 145 152.
29. Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ (2000) The selective serotonin 5-HT1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacologia 152 : 55 66.
30. Delgado JMR, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990) Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47 : 411 418.
31. Duxon MS, Starr KR, Upton N (2000) Latency to paroxetine-induced anxiolysis in the rat is reduced by co-adminstration of the 5-HT1A receptor antagonist WAY100635. Br J Pharmacol 130 : 1713 1719.
32. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281 : 81 88.
33. Gardner CR (1985) Distress vocalization in rat pups a simple screening method for anxiolytic drugs. J Pharmacol Meths 14 : 181 187.
34. Gartside SE, Umbers V, Hajos M, Sharp T (1995) Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115 : 1064 1070.
35. Gobbi M, Crespi D, Foddi MC, Fracasso C, Mancini L, Parotti L, Mennini T (1997) Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn Schmiedeberg's Arch Pharmacol 356 : 22 28.
36. Gobert A, Dekeyne A, Millan MJ (2000) The ability of WAY100635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224289, but not BRL15572. Neuropharmacology 39 : 1608 1616.
37. Gobert A, Rivet JM, Cistarelli L, Millan MJ (1997) Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100635 and GR 127935. J Neurochem 68 : 1159 1163.
38. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120 : 57 66.
39. Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113 : 463 470.
40. Hajos M, Gartside SE, Villa AE, Sharp T (1995) Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience 69 : 189 197.
41. Hajos-Korcsok E, McQuade R, Sharp T (1999) Influence of 5-HT1A receptors on central noradrenergic activity: Microdialysis studies using (±)-MDL 73005EF and its enantiomers. Neuropharmacology 38 : 299 306.
42. Hensler JG (2002) Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacol 26 : 565 573.
43. Hervas I, Vilaro MT, Romero L, Scorza CM, Mengod G, ARTIGAS F (2001) Desensitization of 5-HT1A autoreceptors by a low chronic fluoxetine dose: Effect of the concurrent administration of WAY-100635. Neuropsychopharmacol 24 : 11 20.
44. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000) Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14 : 1777 1785.
45. Hogg S, Dalvi A (2004) Acceleration of onset of action in schedule-induced polydipsia: Combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav 77 : 69 75.
46. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, Stenfors (2003) Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine1B antagonist. J Pharmacol Exp Ther 304 : 1072 1084.
47. Hughes ZA, Scott C, Starr KR, Newson M, Sharp T, Watson JM, Hagan JJ & Dawson LA (2007) Simultaneous blockade of 5-HT1A receptors and the 5-HT transporter results in acute increases in extracellular 5-HT in both rats and guinea pigs: In vivo characterization of the novel 5-HT1A/Breceptor/5-HT transport inhibitor SB-649915-B. Psychopharmacol (Published on-line; doi :).
48. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: Pharmacological characterization. J Pharmacol Exp Ther 277 : 40 47.
49. Koyama T, Nakajima Y, Fujii T, Kawashima K (1999) Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats. Neurosc Lett 265 : 333 336.
50. Kreiss DS, Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274 : 866 876.
51. Le Poul E, Laaris N, Doucet E, Laporte A, Hamon M, Lanfumey L (1995) Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmeideberg's Arch Pharmacol 352 : 141 148.
52. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49 : 281 285.
53. Malagie I, Trillat AC, Jacquot C, Gardier AM (1995) Effects of acute fluoxetine on extracellular serotonin levels in the raphe: An in vivo microdialysis study. Eur J Pharmacol 286 : 213 217.
54. Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M (1999) Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions. Br J Pharmacol 126 : 607 612.
55. McAskill R, Taylor D (1998) Pindolol augmentation of antidepressant therapy. Br J Psychiatry 173 : 203 208.
56. Middlemiss DN, Gothert M, Schlicker E, Scott CM, Selkirk JV, Watson J, Gaster LM, Wyman P, Riley G, Price GW (1999) SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur J Pharmacol 375 : 359 365.
57. Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K (1998) Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Neurosci Res 31 : 23 29.
58. Newman ME, Shalom G, Ran A, Gur E, Van De Kar LD (2004) Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: Regional differences and effects of WAY-100635. Eur J Pharmacol 486 : 25 30.
59. Nomikos GG, Arborelius L, Hook BB, Hacksell U, Svensson TH (1996) The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transmission - General Section 103 : 541 554.
60. Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A (1992) A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature 360 : 161 163.
61. Olivier B, Molewijk HE, Van Der Heydden JA, Van Oorschot R, Ronken E, Mos J, Miczek KA (1998) Ultrasonic vocalizations in rat pups: Effects of serotonergic ligands. Neurosci Biobehav Rev 23 : 215 227.
62. Porsolt D, Bertin A, Jalfre M (1977a) Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229 : 327 336.
63. Porsolt RD, Le Pichon M, Jalfre M (1977b). Depression: A new animal model sensitive to antidepressant treatments. Nature 266 : 730 732.
64. Raap DK, Evans S, Garcia F, Li Q, Muma NA, Wolf WA, Battaglia G, Van Der Kar LD (1999) Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: Reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther 288 : 98 106.
65. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, Grasby PM (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J Psychiatry 158 : 2080 2082.
66. Roberts C, Boyd DF, Middlemiss DN, Routledge C (1999) Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade. Neuropharmacology 38 : 1409 1419.
67. Roberts C, Hatcher P, Hagan JJ, Austin NE, Jeffrey P, Wyman P, Gaster LM, Routledge C, Middlemiss DN (2000) The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea pig. Naunyn Schmiedeberg's Arch Pharmacol 362 : 177 183.
68. Roberts C, Price GW (2001) Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: An in vitro fast cyclic voltammetry study. Neurosci Lett 300 : 45 48.
69. Roberts C, Watson J, Burton M, Price GW, Jones BJ (1996) Functional characterization of the 5-HT terminal autoreceptor in the guinea-pig brain cortex. Br J Pharmacol 117 : 384 388.
70. Romero L, Artigas F (1997) Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors. J Neurochem 68 : 2593 2603.
71. Schechter LE, Mcgonigle P, Barrett JE (1999) Serotonergic antidepressants: Current and future perspectives. Curr Opin Cent Periph Nerv Sys Investig Drugs 1 : 432 447.
72. Scott C, Soffin EM, Hill M, Atkinson PJ, Langmead CJ, Wren PB, Faedo S, Gordon LJ, Price GW, Bromidge S, Watson J et al. (2006) SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue. Eur J Pharmacol 536 : 54 61.
73. Scott C, Watson J, Middlemiss DN, Price GW (2000) 5-HT1B receptor agonist: Antagonist binding affinity differences as a measure of intrinsic activity. Br J Pharmacol 129 : 159P.
74. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Jones BJ, Middlemiss DN, Price GW (1998) SB-224289 - a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 125 : 202 208.
75. Shalom G, Gur E, Van De Kar LD, Newman ME (2004) Repeated administration of the 5-HT1B receptor antagonist SB-224289 blocks the desensitization of 5-HT1B autoreceptors induced by fluoxetine in rat frontal cortex. Naunyn Schmiedeberg's Arch Pharmacol 370 : 84 90.
76. Sharp T, Umbers V, Gartside SE (1997) Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121 : 941 946.
77. Shen C, Li H, Meller E (2002) Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated [35S]GTPγS binding in rat brain regions. Neuropharmacology 42 : 1031 1038.
78. Shopsin B (1978) Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: A rational treatment. Neuropsychobiology 4 : 188 192.
79. Skingle M, BeattiesS DT, Scopes DIC, Starkey SJ, Connor HE, Feniuk W, Tyers MB (1996) GR127935: A potent and selective 5-HT1D receptor antagonist. Behav Brain Res 73 : 157 161.
80. Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS (2007) SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor is anxiolytic and displays fast onset of activity in the rat high light social interaction test. Neuropsychopharmacology (online publication; doi :)
81. Stean TO, Atkins AR, Heidbreder CA, Quinn LP, Trail BK, Upton N (2005) Postsynaptic 5-HT1B receptors modulate electroshock-induced generalised seizures in rats. Br J Pharmacol 144 : 628 635.
82. To CT, Anheuer ZE, Bagdy G (1999) Effects of acute and chronic fluoxetine treatment of CRH-induced anxiety. Neuroreport 25 10 : 553 555.
83. To CT, Bagdy G (1999). Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38 : 279 282.
84. Watson J, Burton M, Price GW, Jones BJ, Middlemiss DN (1996) GR127935 acts as a partial agonist at recombinant human 5-HT1Dα and 5-HT1Dβ receptors. Eur J Pharmacol 314 : 365 372.
85. Watson J, Collin L, Ho M, Riley G, Scott C, Selkirk JV, Price GW (2000) 5-HT1A receptor agonist-antagonist binding affinity differences as a measure of intrinsic activity in recombinant and native tissue systems. Br J Pharmacol 130 : 1108 1114.
86. Yamada M, Yamada M, Higuchi T (2005) Antidepressant-elicited changes in gene expression: Remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 29 : 999 1009.
87. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87 : 173 177.